William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Tarsus Pharmaceuticals (NASDAQ: TARS).The analyst comments "We believe the impressive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE